Iron Triangle Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-146,836
| Closed | -$16.2M | – | 33 |
|
|
2025
Q1 | $16.2M | Sell |
146,836
-171,359
| -54% | -$19M | 2.56% | 20 |
|
|
2024
Q4 | $43.4M | Buy |
+318,195
| New | +$43.4M | 4.78% | 7 |
|
|
2024
Q3 | – | Sell |
-200,000
| Closed | -$27.5M | – | 34 |
|
|
2024
Q2 | $27.5M | Sell |
200,000
-20,000
| -9% | -$2.75M | 2.8% | 18 |
|
|
2024
Q1 | $30.3M | Buy |
+220,000
| New | +$30.3M | 3.11% | 16 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 27 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 28 |
|
|
2023
Q1 | – | Sell |
-100,089
| Closed | -$12M | – | 32 |
|
|
2022
Q4 | $12M | Sell |
100,089
-255,512
| -72% | -$30.5M | 2.14% | 20 |
|
|
2022
Q3 | $37.8M | Buy |
355,601
+5,601
| +2% | +$595K | 6.6% | 3 |
|
|
2022
Q2 | $34.1M | Buy |
+350,000
| New | +$34.1M | 4.42% | 9 |
|